A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nektar Therapeutics stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,500,242 shares of NKTR stock, worth $1.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,500,242
Previous 1,835,742 18.28%
Holding current value
$1.43 Million
Previous $2.28 Million 14.32%
% of portfolio
0.0%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.11 - $1.48 $372,405 - $496,540
-335,500 Reduced 18.28%
1,500,242 $1.95 Million
Q2 2024

Aug 14, 2024

SELL
$0.9 - $1.83 $364,140 - $740,418
-404,600 Reduced 18.06%
1,835,742 $2.28 Million
Q1 2024

May 15, 2024

SELL
$0.49 - $0.96 $406,308 - $796,032
-829,200 Reduced 27.01%
2,240,342 $2.08 Million
Q4 2023

Feb 14, 2024

SELL
$0.42 - $0.57 $285,558 - $387,542
-679,900 Reduced 18.13%
3,069,542 $1.72 Million
Q3 2023

Nov 14, 2023

SELL
$0.51 - $1.05 $27,591 - $56,805
-54,100 Reduced 1.42%
3,749,442 $2.25 Million
Q2 2023

Aug 14, 2023

BUY
$0.53 - $1.03 $667,376 - $1.3 Million
1,259,200 Added 49.49%
3,803,542 $2.21 Million
Q1 2023

May 15, 2023

BUY
$0.64 - $3.15 $1.29 Million - $6.33 Million
2,010,700 Added 376.79%
2,544,342 $1.78 Million
Q4 2022

Feb 14, 2023

SELL
$2.03 - $4.28 $202,999 - $428,000
-100,000 Reduced 15.78%
533,642 $1.21 Million
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.14 $1.43 Million - $2.41 Million
469,100 Added 285.09%
633,642 $2.03 Million
Q2 2022

Aug 15, 2022

BUY
$3.17 - $6.17 $3,170 - $6,170
1,000 Added 0.61%
164,542 $625,000
Q1 2022

May 16, 2022

SELL
$4.16 - $13.72 $210,080 - $692,860
-50,500 Reduced 23.59%
163,542 $881,000
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $1.87 Million - $3.17 Million
172,400 Added 414.01%
214,042 $2.89 Million
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $300,610 - $433,320
23,000 Added 123.38%
41,642 $748,000
Q2 2021

Aug 16, 2021

SELL
$16.52 - $20.4 $77,644 - $95,880
-4,700 Reduced 20.14%
18,642 $320,000
Q1 2021

May 17, 2021

BUY
$16.56 - $25.46 $46,368 - $71,288
2,800 Added 13.63%
23,342 $467,000
Q4 2020

Feb 16, 2021

SELL
$15.77 - $19.03 $392,673 - $473,847
-24,900 Reduced 54.8%
20,542 $349,000
Q3 2020

Nov 16, 2020

BUY
$16.59 - $24.79 $560,742 - $837,902
33,800 Added 290.33%
45,442 $754,000
Q2 2020

Aug 14, 2020

BUY
$16.86 - $23.44 $196,284 - $272,888
11,642 New
11,642 $270,000
Q1 2020

May 15, 2020

SELL
$14.47 - $27.96 $356,569 - $688,990
-24,642 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$15.87 - $23.12 $391,068 - $569,723
24,642 New
24,642 $532,000
Q1 2019

May 15, 2019

SELL
$31.58 - $46.35 $488,605 - $717,127
-15,472 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $7.52 Million - $14 Million
-247,242 Reduced 94.11%
15,472 $509,000
Q3 2018

Nov 14, 2018

SELL
$46.46 - $68.49 $2.21 Million - $3.26 Million
-47,600 Reduced 15.34%
262,714 $16 Million
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $14.4 Million - $32.4 Million
310,314 New
310,314 $15.2 Million
Q1 2018

May 15, 2018

SELL
$57.4 - $108.44 $3.32 Million - $6.27 Million
-57,814 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $238,441 - $626,659
-10,358 Reduced 15.19%
57,814 $3.45 Million
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $1.21 Million - $1.64 Million
68,172
68,172 $1.64 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $178M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.